.Nature Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ sophisticated bosom cancer cells and also energetic or secure human brain metastases revealed steady intracranial activity as well as systemic efficacy of T-DXd.